akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Friday, November 18, 2016

Company News: Curetis Publishes Business and Financial Update for the First Nine Months 2016

- U.S. FDA trial completed with excellent top-line data

- Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.

Recent Operational and Business Highlights

Unyvero US FDA Trial

Thursday, November 17, 2016

Company News: World Antibiotics Day: Reduction of infection risk in femoral head fractures by 66% with antibiotic-loaded bone cement from Heraeus

- New study from Great Britain verifies the advantages of antibiotic-loaded bone cement from Heraeus with femoral head fractures

- Older patients with concomitant diseases profit from locally applied antibiotics

Good news for World Antibiotics Day on November 18th. As local substances carriers, antibiotic-loaded bone cements from Heraeus help in the battle against implant-associated infections in orthopaedics and trauma surgery to prevent infection. This is demonstrated by a new randomised study* from Great Britain in which the use of double-loaded antibiotic bone cement following femoral head fracture led to a significant 66% reduction in infection risk with primary hip arthroplasties, as compared with bone cement with only one antibiotic. The COPAL® G+C antibiotic-loaded bone cement developed by Heraeus Medical contains antibiotics whose spectrum of activity combats the germs typically responsible for infections in the implant.